Literature DB >> 6105058

Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation.

D E Duggan, K F Hooke, S S Hwang.   

Abstract

Sulindac (sulfoxide) is a prodrug in reversible metabolic equilibrium with its pharmacologically active metabolite, the corresponding sulfide. Following simultaneous parenteral injection of sulfoxide-14C and sulfide-3H at equivalent dosage, all labeled species in the plasma of rats and guinea pigs and in representative tissues were determined at various times. Rate constants for sulfoxide in equilibrium or formed from sulfide, calculated from the rates of interchange of the two labels in plasma, are still higher than those approximated from earlier, single-label studies, and indicate turnovers of total body pools every 45 and 8.5 min in rat and guinea pig, respectively. From the time-course of tissue/plasma ratios of endogenous labeled species, it can be concluded that kidney and liver are major sites of bioactivation of the prodrug, with significant sulfoxide leads to sulfide activity present in all tissues examined. At steady state, tissue concentrations of each redox form are determined by the ratio of the metabolic rate constants for the two opposing biotransformations and by unique tissue/plasma distributive constants for each redox form, resulting in all tissues, except lung, and at all times examined, in a sulfide/sulfoxide ratio greater than one.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6105058

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  25 in total

1.  The pharmacokinetics of trilostane and ketotrilostane in an interconverting system in the rat.

Authors:  J P McGee; P N Shaw
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

Review 2.  Signed, Sealed, Delivered: Conjugate and Prodrug Strategies as Targeted Delivery Vectors for Antibiotics.

Authors:  Ana V Cheng; William M Wuest
Journal:  ACS Infect Dis       Date:  2019-04-10       Impact factor: 5.084

3.  Nitric oxide donor exisulind is an effective inhibitor of murine photocarcinogenesis.

Authors:  Tripti Singh; Sandeep C Chaudhary; Puneet Kapur; Zhiping Weng; Craig A Elmets; Levy Kopelovich; Mohammad Athar
Journal:  Photochem Photobiol       Date:  2012-02-24       Impact factor: 3.421

Review 4.  Clinical pharmacokinetics of sulindac. A dynamic old drug.

Authors:  N M Davies; M S Watson
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

Review 5.  Prodrugs. Do they have advantages in clinical practice?

Authors:  V J Stella; W N Charman; V H Naringrekar
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

6.  Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G.

Authors:  Heather N Tinsley; Bernard D Gary; Adam B Keeton; Wei Zhang; Ashraf H Abadi; Robert C Reynolds; Gary A Piazza
Journal:  Mol Cancer Ther       Date:  2009-12       Impact factor: 6.261

7.  NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling.

Authors:  Hu Zhou; Wen Liu; Ying Su; Zhen Wei; Jie Liu; Siva Kumar Kolluri; Hua Wu; Yu Cao; Jiebo Chen; Yin Wu; Tingdong Yan; Xihua Cao; Weiwei Gao; Andrei Molotkov; Fuquan Jiang; Wen-Gang Li; Bingzhen Lin; Hai-Ping Zhang; Jinghua Yu; Shi-Peng Luo; Jin-Zhang Zeng; Gregg Duester; Pei-Qiang Huang; Xiao-Kun Zhang
Journal:  Cancer Cell       Date:  2010-06-15       Impact factor: 31.743

Review 8.  Pharmacologically active metabolites of drugs and other foreign compounds. Clinical, pharmacological, therapeutic and toxicological considerations.

Authors:  D E Drayer
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

9.  Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells.

Authors:  S J Shiff; L Qiao; L L Tsai; B Rigas
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

10.  Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations.

Authors:  Svenja D Steinbrink; Carlo Pergola; Ulrike Bühring; Sven George; Julia Metzner; Astrid S Fischer; Ann-Kathrin Häfner; Joanna M Wisniewska; Gerd Geisslinger; Oliver Werz; Dieter Steinhilber; Thorsten J Maier
Journal:  Cell Mol Life Sci       Date:  2009-11-29       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.